Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting
Name
Lippard_Non-traditional platinum.pdf
Size
877.27 KB
Format
Adobe PDF
Checksum (MD5)
52ddc4f5d230b84eff18581f31de0feb
Author(s)
Lovejoy, Katherine S.
Lippard, Stephen J.
Date Issued
October 2009
Journal
Dalton Transactions
Publisher
Royal Society of Chemistry, The
Citation
Lovejoy, Katherine S., and Stephen J. Lippard. “Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting.” Dalton Transactions, no. 48 (2009): 10651.
Version
Author's final manuscript
Abstract
The five platinum anticancer compounds currently in clinical use conform to structure–activity relationships formulated (M. J. Cleare and J. D. Hoeschele, Bioinorg. Chem., 1973, 2, 187–210) shortly after the discovery that cis-diamminedichloroplatinum(II), cisplatin, has antitumor activity in mice. These compounds are neutral platinum(II) species with two am(m)ine ligands or one bidentate chelating diamine and two additional ligands that can be replaced by water through aquation reactions. The resulting cations ultimately form bifunctional adducts on DNA. Information about the chemistry of these platinum compounds and correlations of their structures with anticancer activity have provided guidance for the design of novel anticancer drug candidates based on the proposed mechanisms of action. This article discusses advances in the synthesis and evaluation of such non-traditional platinum compounds, including cationic and tumor-targeting constructs.
MIT Department
Massachusetts Institute of Technology. Department of Chemistry
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike 3.0
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1039/b913896j
